Andrew Huberman· PhD
So, we gave aspirin, a baby aspirin to people in the first two weeks after the death of their loved one, and looked at whether that was cardioprotective, which of course, it was because, we understand how aspirin works.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
So, we gave aspirin, a baby aspirin to people in the first two weeks after the death of their loved one, and looked at whether that was cardioprotective, which of course, it was because, we understand how aspirin works.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.